Apellis Pharmaceuticals Beheer

Beheer criteriumcontroles 2/4

De CEO Apellis Pharmaceuticals is Cedric Francois, benoemd in Sep2009, heeft een ambtstermijn van 15.33 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 10.37M, bestaande uit 7.1% salaris en 92.9% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 1.41% van de aandelen van het bedrijf, ter waarde € 49.98M. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 5.9 jaar en 9.5 jaar.

Belangrijke informatie

Cedric Francois

Algemeen directeur

US$10.4m

Totale compensatie

Percentage CEO-salaris	7.1%
Dienstverband CEO	15.3yrs
Eigendom CEO	1.4%
Management gemiddelde ambtstermijn	5.9yrs
Gemiddelde ambtstermijn bestuur	9.5yrs

Recente managementupdates

Recent updates

Analyse CEO-vergoeding

Hoe is Cedric Francois's beloning veranderd ten opzichte van Apellis Pharmaceuticals's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Sep 30 2024	n/a	n/a	-US$250m
Jun 30 2024	n/a	n/a	-US$333m
Mar 31 2024	n/a	n/a	-US$417m
Dec 31 2023	US$10m	US$735k	-US$529m
Sep 30 2023	n/a	n/a	-US$606m
Jun 30 2023	n/a	n/a	-US$657m
Mar 31 2023	n/a	n/a	-US$691m
Dec 31 2022	US$9m	US$681k	-US$652m
Sep 30 2022	n/a	n/a	-US$634m
Jun 30 2022	n/a	n/a	-US$638m
Mar 31 2022	n/a	n/a	-US$702m
Dec 31 2021	US$9m	US$647k	-US$746m
Sep 30 2021	n/a	n/a	-US$520m
Jun 30 2021	n/a	n/a	-US$460m
Mar 31 2021	n/a	n/a	-US$360m
Dec 31 2020	US$9m	US$619k	-US$345m
Sep 30 2020	n/a	n/a	-US$536m
Jun 30 2020	n/a	n/a	-US$470m
Mar 31 2020	n/a	n/a	-US$423m
Dec 31 2019	US$4m	US$560k	-US$305m
Sep 30 2019	n/a	n/a	-US$228m
Jun 30 2019	n/a	n/a	-US$194m
Mar 31 2019	n/a	n/a	-US$156m
Dec 31 2018	US$4m	US$550k	-US$128m

Compensatie versus markt: De totale vergoeding ($USD 10.37M ) Cedric } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de German markt ($USD 2.08M ).

Compensatie versus inkomsten: De vergoeding van Cedric is gestegen terwijl het bedrijf verliesgevend is.

CEO

Cedric Francois (52 yo)

15.3yrs

Tenure

US$10,373,049

Compensatie

Dr. Cedric Francois, M.D., Ph.D. serves as Principal of Vista Therapeutics, Inc. Dr. Francois co-founded Apellis Pharmaceuticals, Inc. in 2009 and has been its Chief Executive Officer, President and Direct...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Cedric Francois	Co-Founder	15.3yrs	US$10.37m	1.41% € 50.0m
Alec Machiels	Co-Founder & Director	16yrs	US$495.96k	0.63% € 22.4m
Timothy Sullivan	CFO & Treasurer	7.3yrs	US$3.74m	0.099% € 3.5m
Adam Townsend	Chief Operating Officer	1yr	US$3.71m	0.034% € 1.2m
David Watson	General Counsel	11yrs	US$4.89m	0.10% € 3.7m
Caroline Baumal	Chief Medical Officer	2yrs	US$4.43m	0.014% € 481.6k
Pascal Deschatelets	Co-Founder & Chief Scientific Officer	15.3yrs	US$3.08m	0.90% € 32.0m
James Chopas	VP, Corporate Controller & Chief Accounting Officer	3.4yrs	geen gegevens	0.014% € 507.9k
Meredith Kaya	Senior Vice President	no data	geen gegevens	geen gegevens
Karen Lewis	Chief People Officer	4.7yrs	geen gegevens	0.012% € 437.5k
Peter Hillmen	Head of Hematology Engagement & Member of PNH Scientific Advisory Board	2.7yrs	geen gegevens	geen gegevens
Victoria Brown	Senior Vice President	5.9yrs	geen gegevens	geen gegevens

5.9yrs

Gemiddelde duur

51.5yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van 1JK is doorgewinterd en ervaren (gemiddelde ambtstermijn van 5.9 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Cedric Francois	Co-Founder	15.3yrs	US$10.37m	1.41% € 50.0m
Alec Machiels	Co-Founder & Director	15.3yrs	US$495.96k	0.63% € 22.4m
Peter Hillmen	Head of Hematology Engagement & Member of PNH Scientific Advisory Board	9.5yrs	geen gegevens	geen gegevens
Lokchung L. Chan	Independent Chairman of the Board	11.5yrs	US$504.08k	0.014% € 506.1k
Stephanie O'Brien	Independent Director	11.5yrs	US$488.46k	0.014% € 506.1k
Gabriel Coscas	Member of AMD Scientific Advisory Board	9.5yrs	geen gegevens	geen gegevens
Robert Brodsky	Member of PNH Scientific Advisory Board	9.5yrs	geen gegevens	geen gegevens
Michael Yeadon	Member of Pulmonology Scientific Advisory Board	9.5yrs	geen gegevens	geen gegevens
Paul Fonteyne	Independent Director	4.8yrs	US$489.08k	0.0046% € 162.2k
A. Dunlop	Independent Director	14.8yrs	US$480.96k	0.12% € 4.3m
Marsha Wills-Karp	Member of Pulmonology Scientific Advisory Board	no data	geen gegevens	geen gegevens
Carl Atkinson	Member of Pulmonology Scientific Advisory Board	9.5yrs	geen gegevens	geen gegevens

9.5yrs

Gemiddelde duur

57.5yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van 1JK wordt beschouwd als ervaren (gemiddelde ambtstermijn 9.5 jaar).

Bedrijfsanalyse en status van financiële gegevens

Gegevens	Laatst bijgewerkt (UTC-tijd)
Bedrijfsanalyse	2025/01/26 07:33
Aandelenkoers aan het einde van de dag	2025/01/24 00:00
Inkomsten	2024/09/30
Jaarlijkse inkomsten	2023/12/31

Gegevensbronnen

De gegevens die gebruikt zijn in onze bedrijfsanalyse zijn afkomstig van S&P Global Market Intelligence LLC. De volgende gegevens worden gebruikt in ons analysemodel om dit rapport te genereren. De gegevens zijn genormaliseerd, waardoor er een vertraging kan optreden voordat de bron beschikbaar is.

Pakket	Gegevens	Tijdframe	Voorbeeld Amerikaanse bron ^*
Financiële gegevens bedrijf	10 jaar	Resultatenrekening Kasstroomoverzicht Balans	SEC-formulier 10-K SEC-formulier 10-Q
Consensus schattingen analisten	+3 jaar	Financiële prognoses Koersdoelen analisten	Onderzoeksrapporten van analisten Blue Matrix
Marktprijzen	30 jaar	Aandelenprijzen Dividenden, splitsingen en acties	ICE Marktgegevens SEC-formulier S-1
Eigendom	10 jaar	Top aandeelhouders Handel met voorkennis	SEC-formulier 4 SEC-formulier 13D
Beheer	10 jaar	Leiderschapsteam Raad van bestuur	SEC-formulier 10-K SEC-formulier DEF 14A
Belangrijkste ontwikkelingen	10 jaar	Bedrijfsaankondigingen	SEC-formulier 8-K

^* voorbeeld voor effecten uit de VS, voor niet-Amerikaanse effecten worden gelijkwaardige regelgevingsformulieren en bronnen gebruikt.

Tenzij anders vermeld zijn alle financiële gegevens gebaseerd op een jaarperiode, maar worden ze elk kwartaal bijgewerkt. Dit staat bekend als Trailing Twelve Month (TTM) of Last Twelve Month (LTM) gegevens. Lees hier meer.

Analysemodel en Snowflake

Details van het analysemodel dat is gebruikt om dit rapport te genereren, zijn beschikbaar op onze Github-pagina. We hebben ook handleidingen voor het gebruik van onze rapporten en tutorials op Youtube.

Leer meer over het team van wereldklasse dat het Simply Wall St-analysemodel heeft ontworpen en gebouwd.

Industrie en sector

Onze industrie- en sectormetrics worden elke 6 uur berekend door Simply Wall St, details van ons proces zijn beschikbaar op .

Bronnen van analisten

Apellis Pharmaceuticals, Inc. wordt gevolgd door 34 analisten. 21 van deze analisten hebben de schattingen van de omzet of winst ingediend die zijn gebruikt als input voor ons rapport. Inzendingen van analisten worden de hele dag door bijgewerkt.

Analist	Instelling
Colleen Kusy	Baird
Michael Ulz	Baird
Ishan Majumdar	Baptista Research

Apellis Pharmaceuticals Beheer

Beheer criteriumcontroles 2/4

Belangrijke informatie

Recente managementupdates

Apellis Pharmaceuticals, Inc. Announces Executive Changes

Apellis Pharmaceuticals Appoints Keli Walbert to the Board of Directors

Apellis Pharmaceuticals, Inc., Annual General Meeting, Jun 05, 2024

Chief Technical Operations Officer recently sold €590k worth of stock

Apellis Pharmaceuticals, Inc. Announces Appointment of Philip Ferrone, M.D as Chief Medical Retina Advisor, Effective March 18, 2024

Apellis Pharmaceuticals, Inc. Appoints Adam Townsend as Chief Operating Officer

Recent updates

Apellis Pharmaceuticals, Inc. Announces Executive Changes

Apellis Pharmaceuticals Appoints Keli Walbert to the Board of Directors

Third quarter 2024 earnings released: US$0.46 loss per share (vs US$1.17 loss in 3Q 2023)

Sobi and Apellis Pharmaceuticals, Inc. Announces Detailed Data from the Phase 3 Valiant Study

Apellis Pharmaceuticals, Inc. Presents Positive Results from the Phase 3 VALIANT Study at Kidney Week

Forecast breakeven date pushed back to 2026

Sobi and Apellis Announce Positive Topline Results from Phase 3 Valiant Study of Pegcetacoplan in C3G and Primary IC-MPGN

Forecast to breakeven in 2025

Second quarter 2024 earnings released: US$0.30 loss per share (vs US$1.02 loss in 2Q 2023)

Apellis Pharmaceuticals, Inc. Announces Positive One-Year Data from Phase 2 Study of Pegcetacoplan in Post-Transplant Recurrence of C3G and IC-MPGN Presented as Late-Breaker at ERA Congress

First quarter 2024 earnings released: US$0.54 loss per share (vs US$1.56 loss in 1Q 2023)

Apellis Pharmaceuticals, Inc., Annual General Meeting, Jun 05, 2024

Apellis Announces Pegcetacoplan MAA Review Reset to Initial Assessment by European Medicines Agency

Chief Technical Operations Officer recently sold €590k worth of stock

Apellis Pharmaceuticals, Inc. Announces Appointment of Philip Ferrone, M.D as Chief Medical Retina Advisor, Effective March 18, 2024

Full year 2023 earnings released: US$4.45 loss per share (vs US$6.15 loss in FY 2022)

Apellis Pharmaceuticals, Inc. Announces Negative CHMP Opinion for Pegcetacoplan for Ga in the European Union and Plans to Seek Re-Examination of Application

Apellis Pharmaceuticals, Inc. Appoints Adam Townsend as Chief Operating Officer

Co-Founder recently sold €482k worth of stock

Apellis Pharmaceuticals, Inc. Provides Update on Ongoing Regulatory Review of Pegcetacoplan for GA in the European Union

Apellis Pharmaceuticals, Inc. and Sobi Presents Post Hoc Data that Reinforce the Long-Term Efficacy and Safety of EMPAVELI

Insufficient new directors

Apellis Pharmaceuticals, Inc. has filed a Follow-on Equity Offering in the amount of $300 million.

Sobi and Apellis Pharmaceuticals, Inc. Announce Positive Results from Phase 2 NOBLE Results of Pegcetacoplan in Post-Transplant Recurrence of Primary IC-MPGN and C3G

Apellis Pharmaceuticals, Inc. Announces U.S. FDA Approval of the EMPAVELI® Injector, a Device to Streamline Self-Administration

Apellis Pharmaceuticals, Inc. Receives Permanent J-Code (J2781) for SYFOVRE® (Pegcetacoplan Injection), Effective October 1, 2023

Levi & Korsinsky, LLP Notifies Investors in Apellis Pharmaceuticals, Inc. of Class Action Securities Lawsuit

Apellis Pharmaceuticals, Inc. Announces Corporate Restructuring to Drive Growth of SYFOVRE and EMPAVELI

Apellis Pharmaceuticals, Inc. Provides Updates on Injection Kits and Rare Safety Events with SYFOVRE (Pegcetacoplan Injection)

Kessler Topaz Meltzer & Check, LLP and Bernstein Litowitz Berger & Grossmann LLP Files Securities Class Action Lawsuit Against Apellis Pharmaceuticals, Inc

No longer forecast to breakeven

Second quarter 2023 earnings released: US$1.02 loss per share (vs US$1.46 loss in 2Q 2022)

Apellis Pharmaceuticals, Inc. Provides Update on Review of Rare Safety Events with SYFOVRE® for Geographic Atrophy

Insufficient new directors

FDA Approves Syfovre (Pegcetacoplan Injection) as the First and Only Treatment for Geographic Atrophy (GA)

Apellis Appoints Retina Specialist Dr. Caroline Baumal as Chief Medical Officer

Forecast to breakeven in 2025

Apellis Announces FDA Acceptance of NDA Amendment and New PDUFA Date of February 26, 2023 for Pegcetacoplan for Geographic Atrophy (GA)

Insufficient new directors

Apellis Pharmaceuticals, Inc. Announces Plans to Submit 24-Month Phase 3 Data to the FDA for Pegcetacoplan NDA for Geographic Atrophy

Apellis Pharmaceuticals, Inc. Announces 24-Month Phase 3 Post Hoc Results Showing Treatment with Pegcetacoplan Led to Preservation of Function in High-Risk Areas of the Retina in Patients with Geographic Atrophy (GA) at AAO Annual Meeting

Apellis Pharmaceuticals, Inc. Announces 24-Month Results Showing Increased Effects Over Time with Pegcetacoplan in Phase 3 DERBY and OAKS Studies in Geographic Atrophy

Apellis Pharmaceuticals, Inc. Announces FDA Acceptance and Priority Review of the New Drug Application for Pegcetacoplan for the Treatment of Geographic Atrophy

Apellis Pharmaceuticals, Inc. Announces Five Oral Presentations in Geographic Atrophy Highlighted at the ASRS Annual Scientific Meeting

Insider recently sold €116k worth of stock

Apellis Pharmaceuticals, Inc. and Sobi(R) Report New Data Reinforcing the Robust Efficacy and Safety Profile of EMPAVELI (pegcetacoplan) for PNH at EHA 2022 Congress

Apellis Pharmaceuticals, Inc. and Sobi Announces First Patient Dosed in Phase 3 VALIANT Study of Pegcetacoplan for IC-MPGN and C3G, Rare Kidney Diseases with High Unmet Medical Need

Apellis Announces Submission of New Drug Application to the FDA for Pegcetacoplan for Geographic Atrophy

No longer forecast to breakeven

Apellis Pharmaceuticals, Inc. Announces Appointment of Peter Hillmen as Head of Hematology Engagement, Effective May 23, 2022

Apellis Pharmaceuticals, Inc. Announces Detailed 18-Month Results from Phase 3 DERBY and OAKS Studies of Pegcetacoplan for Geographic Atrophy at ARVO Annual Meeting

Insufficient new directors

Apellis Pharmaceuticals, Inc., Annual General Meeting, Jun 01, 2022

No longer forecast to breakeven

Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat

General Counsel recently sold €51k worth of stock

Forecast to breakeven in 2024

Apellis Pharmaceuticals, Inc. and Swedish Orphan Biovitrum AB (Publ) Announce EU Approval of Aspaveli® (Pegcetacoplan) for Treatment of PNH

Apellis Pharmaceuticals, Inc. and Swedish Orphan Biovitrum AB (publ) Report Empaveli™ Demonstrated Sustained Normalization of Clinical Measures in a Broad PNH Patient Population

Apellis Announces Results from Phase 3 DERBY and OAKS Studies in Geographic Atrophy (GA) and Plans to Submit NDA to FDA in the First Half of 2022

Apellis Pharmaceuticals, Inc. and Swedish Orphan Biovitrum AB (Publ) Report Positive Top-Line Results from the Phase 3 Prince Study of EMPAVELI™ (pegcetacoplan) in Treatment-naïve Patients with PNH

Apellis Announces U.S. Food and Drug Administration (Fda) Approval of Empaveli™ (Pegcetacoplan) for Adults with Paroxysmal Nocturnal Hemoglobinuria (PNH)

ApApellis Pharmaceuticals, Inc. to Present Long-Term Pegcetacoplan Data in PNH at the European Hematology Association Virtual Congress

The NEJM Publishes Phase 3 PEGASUS Study Results Comparing Pegcetacoplan to Eculizumab for PNH

Apellis Pharmaceuticals, Inc. Provides Update on APL-9 for Severe COVID-19

New 90-day high: €46.60

Apellis Pharmaceuticals, Inc. Enters into A Commercial Supply Agreement with Bachem Americas, Inc

New 90-day high: €45.40

Swedish Orphan Biovitrum AB and Apellis Pharmaceuticals Inc. Reports Positive Top-Line Results At 48 Weeks from the Phase 3 Pegasus Study of Pegcetacoplan in PNH